ADMA logo

ADMA Biologics (ADMA) EBITDA

annual EBITDA:

$140.03M+$134.91M(+2635.00%)
December 31, 2024

Summary

  • As of today (June 1, 2025), ADMA annual EBITDA is $140.03 million, with the most recent change of +$134.91 million (+2635.00%) on December 31, 2024.
  • During the last 3 years, ADMA annual EBITDA has risen by +$193.13 million (+363.74%).
  • ADMA annual EBITDA is now at all-time high.

Performance

1-year change

+2635%

3-year change

+363.74%

5-year change

+488.68%

15-year change

+470.64%

ADMA EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

88.36%
ADMA annual EBITDA is higher than 88.36% of companies in Healthcare sector

Range

All-time high

$140.03M
ADMA annual EBITDA is currently at an all-time high

3-year low

-$53.09M

Earnings dates

Last annual earnings report date

Dec 31, 2024
ADMA previous annual earnings announcement was published on Dec 31, 2024

Next annual earnings report date

N/A
ADMA next annual earnings announcement has not yet been scheduled

OtherADMAincome statement metrics

Annual revenue

$426.45M
ADMA annual revenue is $426.45 million

annual net income

$197.67M
ADMA annual net profit is $197.67 million

annual EBIT

$139.64M
ADMA annual earnings before interest & taxes is $139.64 million

Annual EPS

$0.81
ADMA annual earnings per share is $0.81

quarterly EBITDA:

$35.45M-$4.09M(-10.33%)
March 31, 2025

Summary

  • As of today (June 1, 2025), ADMA quarterly EBITDA is $35.45 million, with the most recent change of -$4.09 million (-10.33%) on March 31, 2025.
  • Over the past year, ADMA quarterly EBITDA has increased by +$11.17 million (+45.98%).
  • ADMA quarterly EBITDA is now -15.97% below its all-time high of $42.19 million, reached on September 30, 2024.

Performance

3-month change

-10.33%

1-year change

+45.98%

3-year change

+277%

5-year change

+325.23%

ADMA quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

86.09%
ADMA quarterly EBITDA is higher than 86.09% of companies in Healthcare sector

Range

All-time high

$42.19M
ADMA quarterly EBITDA is currently -15.97% below its historical high of $42.19 million

3-year low

-$20.03M

Earnings dates

Last quarterly earnings report date

Mar 31, 2025
ADMA previous earnings announcement was published on Mar 31, 2025

Next quarterly earnings report date

Aug 8, 2025
ADMA next earnings announcement is scheduled for Aug 8, 2025

OtherADMAincome statement metrics

Quarterly revenue

$114.80M
ADMA quarterly revenue is $114.80 million

quarterly net income

$26.90M
ADMA quarterly net profit is $26.90 million

quarterly EBIT

$35.42M
ADMA quarterly earnings before interest & taxes is $35.42 million

Quarterly EPS

$0.11
ADMA quarterly earnings per share is $0.11

TTM EBITDA:

$158.85M+$11.17M(+7.56%)
March 31, 2025

Summary

  • As of today (June 1, 2025), ADMA TTM EBITDA is $158.85 million, with the most recent change of +$11.17 million (+7.56%) on March 31, 2025.
  • Over the past year, ADMA TTM EBITDA has increased by +$130.81 million (+466.45%).
  • ADMA TTM EBITDA is now at all-time high.

Performance

3-month change

+7.56%

1-year change

+466.45%

3-year change

+368.48%

5-year change

+487.03%

ADMA TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

87.71%
ADMA TTM EBITDA is higher than 87.71% of companies in Healthcare sector

Range

All-time high

$158.85M
ADMA TTM EBITDA is currently at an all-time high

3-year low

-$59.17M

Earnings dates

Last quarterly earnings report date

Mar 31, 2025
ADMA previous earnings announcement was published on Mar 31, 2025

Next quarterly earnings report date

Aug 8, 2025
ADMA next earnings announcement is scheduled for Aug 8, 2025

OtherADMAincome statement metrics

TTM revenue

$459.38M
ADMA TTM revenue is $459.38 million

TTM net income

$206.77M
ADMA TTM net profit is $206.77 million

TTM EBIT

$152.90M
ADMA TTM earnings before interest & taxes is $152.90 million

TTM EPS

$0.85
ADMA TTM earnings per share is $0.85

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

annual EBITDA

$140.03M
ADMA annual EBITDA is $140.03 million

annual net income

$197.67M
ADMA annual net profit is $197.67 million

annual interest expense

$13.93M
ADMA annual interest expense is $13.93 million

annual income tax

-$71.96M
ADMA annual income tax is -$71.96 million

annual D&A

$8.04M
ADMA annual depreciation & amortization is $8.04 million

ADMA EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+2635.0%+46.0%+466.4%
3 y3 years+363.7%+277.0%+368.5%
5 y5 years+488.7%+325.2%+487.0%

ADMA EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+363.7%-16.0%+277.0%at high+368.5%
5 y5-yearat high+334.1%-16.0%+277.0%at high+365.6%
alltimeall timeat high+334.1%-16.0%+277.0%at high+365.6%

ADMA EBITDA History

DateAnnualQuarterlyTTM
Mar 2025
-
$35.45M(-10.3%)
$158.85M(+7.6%)
Dec 2024
$140.03M(+2635.0%)
$39.54M(-6.3%)
$147.69M(+49.4%)
Sep 2024
-
$42.19M(+1.2%)
$98.83M(+46.0%)
Jun 2024
-
$41.68M(+71.6%)
$67.70M(+141.4%)
Mar 2024
-
$24.28M(-360.5%)
$28.04M(+447.8%)
Dec 2023
$5.12M(-113.0%)
-$9.32M(-184.3%)
$5.12M(-48.2%)
Sep 2023
-
$11.05M(+445.7%)
$9.88M(-214.5%)
Jun 2023
-
$2.03M(+49.1%)
-$8.63M(-52.4%)
Mar 2023
-
$1.36M(-129.8%)
-$18.12M(-54.1%)
Dec 2022
-$39.51M(-25.6%)
-$4.56M(-38.9%)
-$39.51M(-15.5%)
Sep 2022
-
-$7.46M(-0.1%)
-$46.77M(-10.6%)
Jun 2022
-
-$7.47M(-62.7%)
-$52.30M(-11.6%)
Mar 2022
-
-$20.03M(+69.5%)
-$59.17M(+11.4%)
Dec 2021
-$53.09M(-11.2%)
-$11.82M(-9.1%)
-$53.09M(-5.8%)
Sep 2021
-
-$12.99M(-9.4%)
-$56.35M(+0.4%)
Jun 2021
-
-$14.33M(+2.7%)
-$56.14M(-3.3%)
Mar 2021
-
-$13.95M(-7.4%)
-$58.04M(-3.0%)
Dec 2020
-$59.82M(+66.0%)
-$15.07M(+17.8%)
-$59.82M(+15.6%)
Sep 2020
-
-$12.79M(-21.2%)
-$51.76M(+10.3%)
Jun 2020
-
-$16.23M(+3.1%)
-$46.94M(+14.4%)
Mar 2020
-
-$15.74M(+124.8%)
-$41.04M(+13.9%)
Dec 2019
-$36.03M(-36.5%)
-$7.00M(-12.2%)
-$36.03M(-19.4%)
Sep 2019
-
-$7.97M(-22.9%)
-$44.70M(-9.9%)
Jun 2019
-
-$10.33M(-3.6%)
-$49.62M(-4.3%)
Mar 2019
-
-$10.72M(-31.6%)
-$51.83M(-8.7%)
Dec 2018
-$56.77M(+50.3%)
-$15.68M(+21.7%)
-$56.77M(+10.5%)
Sep 2018
-
-$12.89M(+2.7%)
-$51.38M(-1.3%)
Jun 2018
-
-$12.54M(-20.0%)
-$52.08M(+9.3%)
Mar 2018
-
-$15.67M(+52.4%)
-$47.65M(+26.1%)
Dec 2017
-$37.78M
-$10.28M(-24.3%)
-$37.78M(+20.7%)
Sep 2017
-
-$13.58M(+67.4%)
-$31.31M(+46.7%)
DateAnnualQuarterlyTTM
Jun 2017
-
-$8.12M(+39.9%)
-$21.34M(+14.8%)
Mar 2017
-
-$5.80M(+52.1%)
-$18.58M(+10.6%)
Dec 2016
-$16.81M(+7.3%)
-$3.81M(+5.7%)
-$16.81M(-1.1%)
Sep 2016
-
-$3.61M(-32.7%)
-$16.99M(-5.2%)
Jun 2016
-
-$5.36M(+33.1%)
-$17.92M(+7.5%)
Mar 2016
-
-$4.03M(+0.6%)
-$16.67M(+6.5%)
Dec 2015
-$15.66M(-1.1%)
-$4.00M(-11.8%)
-$15.66M(+2.4%)
Sep 2015
-
-$4.54M(+10.4%)
-$15.29M(+11.2%)
Jun 2015
-
-$4.11M(+36.4%)
-$13.75M(+4.1%)
Mar 2015
-
-$3.01M(-17.2%)
-$13.21M(-16.5%)
Dec 2014
-$15.83M(+7.7%)
-$3.64M(+21.4%)
-$15.83M(-5.1%)
Sep 2014
-
-$3.00M(-16.1%)
-$16.68M(+3.2%)
Jun 2014
-
-$3.57M(-36.6%)
-$16.15M(-6.4%)
Mar 2014
-
-$5.63M(+25.6%)
-$17.26M(+17.4%)
Dec 2013
-$14.70M(+90.7%)
-$4.48M(+81.4%)
-$14.70M(+7.1%)
Sep 2013
-
-$2.47M(-47.2%)
-$13.72M(-1.7%)
Jun 2013
-
-$4.68M(+52.4%)
-$13.96M(+33.7%)
Mar 2013
-
-$3.07M(-12.5%)
-$10.44M(+22.4%)
Dec 2012
-$7.71M(>+9900.0%)
-$3.51M(+29.3%)
-$8.53M(+69.4%)
Sep 2012
-
-$2.71M(+134.2%)
-$5.04M(+116.0%)
Jun 2012
-
-$1.16M(-0.3%)
-$2.33M(+96.6%)
Mar 2012
-
-$1.16M(>+9900.0%)
-$1.19M(+3839.9%)
Dec 2011
-
-$8300.00(+59.6%)
-$30.10K(+11.5%)
Sep 2011
-
-$5200.00(-55.6%)
-$27.00K(+2.3%)
Jun 2011
-$26.50K(+29.3%)
-$11.70K(+138.8%)
-$26.40K(+18.4%)
Mar 2011
-
-$4900.00(-5.8%)
-$22.30K(+0.5%)
Dec 2010
-
-$5200.00(+13.0%)
-$22.20K(+4.2%)
Sep 2010
-
-$4600.00(-39.5%)
-$21.30K(+27.5%)
Jun 2010
-
-$7600.00(+58.3%)
-$16.70K(+83.5%)
Jun 2010
-$20.50K
-
-
Mar 2010
-
-$4800.00(+11.6%)
-$9100.00(+111.6%)
Dec 2009
-
-$4300.00
-$4300.00

FAQ

  • What is ADMA Biologics annual EBITDA?
  • What is the all time high annual EBITDA for ADMA Biologics?
  • What is ADMA Biologics annual EBITDA year-on-year change?
  • What is ADMA Biologics quarterly EBITDA?
  • What is the all time high quarterly EBITDA for ADMA Biologics?
  • What is ADMA Biologics quarterly EBITDA year-on-year change?
  • What is ADMA Biologics TTM EBITDA?
  • What is the all time high TTM EBITDA for ADMA Biologics?
  • What is ADMA Biologics TTM EBITDA year-on-year change?

What is ADMA Biologics annual EBITDA?

The current annual EBITDA of ADMA is $140.03M

What is the all time high annual EBITDA for ADMA Biologics?

ADMA Biologics all-time high annual EBITDA is $140.03M

What is ADMA Biologics annual EBITDA year-on-year change?

Over the past year, ADMA annual EBITDA has changed by +$134.91M (+2635.00%)

What is ADMA Biologics quarterly EBITDA?

The current quarterly EBITDA of ADMA is $35.45M

What is the all time high quarterly EBITDA for ADMA Biologics?

ADMA Biologics all-time high quarterly EBITDA is $42.19M

What is ADMA Biologics quarterly EBITDA year-on-year change?

Over the past year, ADMA quarterly EBITDA has changed by +$11.17M (+45.98%)

What is ADMA Biologics TTM EBITDA?

The current TTM EBITDA of ADMA is $158.85M

What is the all time high TTM EBITDA for ADMA Biologics?

ADMA Biologics all-time high TTM EBITDA is $158.85M

What is ADMA Biologics TTM EBITDA year-on-year change?

Over the past year, ADMA TTM EBITDA has changed by +$130.81M (+466.45%)
On this page